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Abstract 
The objective of this register-based cohort study was to examine the relationship 
between hypertensive disorders of pregnancy and future hospital discharges from 
specified causes including cardiovascular disease, incident cancer registrations and 
mortality. From the Aberdeen Maternity and Neonatal Databank we identified 34,854 
women who were born on or before 31st December 1967 and who had (i) 
preeclampsia/eclampsia, (ii) gestational hypertension or (iii) normal blood pressure in 
their first pregnancy. Hospital discharges from selected causes including 
cardiovascular disease, cancer registrations and deaths in these women were 
identified from the Scottish Morbidity Records. 
There were 2,026 women who had preeclampsia, 8,891 who had gestational 
hypertension and 23,937 who were normotensive during their first pregnancy. 
Compared to normotensive women, women with preeclampsia had a higher mortality 
from ischaemic heart disease (adj. IRR 1.38, 95% CI 1.03, 1.84) and circulatory 
disease (adj. IRR 1.30, 95% CI 1.06, 1.60). Similar trends were seen with gestational 
hypertension. There was no difference in all cause mortality in the three groups. The 
odds of a hypertensive episode were higher in women with preeclampsia (adj. OR 
1.79, 95% CI 1.55, 2.05) and gestational hypertension (adj. OR 1.68, 95% CI 1.55, 
1.82) compared to normotensives. Compared to normotensives, women with 
gestational hypertension (adj. IRR 0.91, 95% CI 0.85, 0.96) or preeclampsia (adj. IRR 
0.86, 95% CI 0.77, 0.97) had lower incidences of cancer. 
 Women with pregnancy induced hypertension are at a higher risk of incidence and 
mortality from ischaemic heart disease and a lower risk of cancer. 
Key words: preeclampsia, gestational hypertension, mortality, cancer, cardiovascular 
disease 
 
 
 
Introduction: 
Historically, hypertensive disorders of pregnancy were believed to be self limiting, 
with minimal residual effects on health once the pregnancy had ended. However, 
several primary studies1-5 and two meta-analyses6, 7 have shown that hypertensive 
problems in pregnancy - including gestational hypertension, toxaemia of pregnancy 
(the term previously used for what is now called preeclampsia), preeclampsia and/or 
eclampsia may be associated with an increased risk of hypertension, ischaemic heart 
disease and stroke later in life.  Several studies have also examined future mortality 
risk, with conflicting results8-10. Conflicting results have also been reported regarding 
the risk of cancer in women with preeclampsia11, 12. 
Between 1996 and 1999, the Aberdeen Study of Cardiovascular Disease in Women 
(ASCHW) explored the subsequent cardiovascular health of 3593 women who had 
pre-eclampsia/eclampsia; gestational hypertension or normotension  during their first 
pregnancy which ended with a live singleton birth between 1951 and 19703. 
Cardiovascular health was assessed using a postal questionnaire, clinical 
examination and linkage to hospital discharge and mortality data. Compared to 
women with a normotensive first pregnancy, those with gestational hypertension or 
preeclampsia/eclampsia were more likely to have subsequent hypertension; 
preeclamptic/eclamptic women also had higher rates of hospital admission for, and 
deaths from, cerebrovascular disease. At the time of the study the number of 
cardiovascular events was relatively small.  In this paper, we examine the relationship 
between hypertensive disorders of pregnancy and future risk of hospital discharge for 
selected conditions, cancer and death using the expanded ASCHW cohort who are 
now older and therefore likely to have more outcome events.  
 
 
 
 
Methods  
Identification of cohort 
The Aberdeen Maternity and Neonatal Databank (AMND) has contemporaneously 
recorded and stored information on all pregnancy related events occurring in 
Aberdeen from 1950 to the present day. Standardised coding criteria are used to 
define and record hypertensive disorders of pregnancy in the AMND13. From the 
AMND we identified all women who were born before 1968 and who were living in 
Aberdeen City and District at the time of their first pregnancy. Women who had 
pregnancy induced hypertension (either gestational hypertension or pre-
eclampsia/eclampsia) in their first pregnancy formed the exposed groups. All women 
who were normotensive in their first pregnancy formed the unexposed, comparison 
group. Gestational hypertension was defined as diastolic pressure > 90 mm Hg on 
two occasions at least four hours apart or a single reading of >110 mm Hg; from 20 
weeks gestation onwards in a previously normotensive woman. Pre-eclampsia was 
defined as gestational hypertension plus at least one episode of proteinuria of 0.3 
g/24 hours. Eclampsia was defined clinically as convulsions occurring in the presence 
of pre-eclampsia.  In this paper women with pre-eclampsia and those with eclampsia 
were considered together as one group. Women with chronic hypertension diagnosed 
at the first antenatal booking visit are identified separately in the AMND, and were 
excluded from this study. Women who had twins or other multiple gestations were 
also excluded.  
Data linkage  
The Information and Statistics Division (ISD) of the NHS National Services, Scotland 
linked the AMND records with details of all subsequent hospital discharges (Scottish 
Morbidity Record, SMR01), cancer registrations (SMR06) and death registrations 
(General Register Office for Scotland, GRO-S) occurring in members of the cohort. 
ISD holds relevant morbidity and mortality data for all individuals who have ever been 
resident in Scotland. The cancer registry has been collecting information on all new 
cases of cancer in Scotland since 1958.  The Scottish Morbidity Records have 
reliable information on all hospital discharges since 1980. Information was available 
at the time of data linkage about cancer registrations up to 31st January 2007, hospital 
discharges to 31st December 2007 and deaths to 31st March 2008.  The data linkage 
process used probability matching based on first name, surname, previous surname 
and date of birth. Any obvious mismatches were checked manually by ISD data 
analysts. After ISD had linked the AMND records with their data, all personal 
identifying information was removed before the linked dataset was released to us.  
Outcome events were coded by ISD or GRO-S, using the International Classification 
of Disease (ICD) 9th revision until April 1996, and the 10th revision thereafter.  
Outcomes were categorised as: hypertension (ICD-9: 401-4; ICD-10: I10-4); 
ischaemic heart disease (410-4, 428; I20-5, I50); cerebrovascular disease (430-8; 
I60-9); kidney disease (580-99; N00-39); other circulatory disease (390-8, 405, 415-
27, 440-59;  I00-9, I15, I26-8, I30-49, I51-2, I70-99), all circulatory disease (390-459; 
I00-I99, G45). The site of cancer were recorded as ICD-9 codes (140–239) and/ or 
ICD–10 (Any C or D categories). 
 
Statistical analysis  
We used chi square and t tests as appropriate to test for baseline differences among 
the three groups of women. For all analyses, we used the normotensive group as the 
referent group. Mortality differences between groups were examined by calculating 
unadjusted and adjusted incident rate ratios (IRRs) using Poisson regression in 
STATA version 11(Stata Corp., Texas, USA).  Adjustments were made for: year of 
birth, smoking status and social class of the women at the time of their first 
pregnancy. For many women, smoking behaviour at time of booking was not 
recorded. Smoking status was included in the models as yes, no and unknown status, 
to avoid excluding a large number of women from the analyses. Key analyses were 
repeated excluding any women with unknown smoking status. Social class has been 
coded in the AMND according to the British Registrar General’s occupational social 
class classification of 1951: I- professional, II- managerial, IIIa- skilled non-manual, 
IIIb- skilled manual, IV- semi-skilled, V- unskilled 14. This is allocated on the basis of 
the partner’s social class if available or the woman’s own social class if she has no 
partner.  
This Poisson regression approach was also used when examining the cancer 
registrations, since the date of first cancer registration was known. We excluded 
women who had a date of first cancer registration prior to delivery and women who 
had their delivery date after the final follow-up date for our extraction from the cancer 
register (31st January 2007). 
Hospital discharge data held by ISD do not indicate whether the episode was the first 
event.  Since we did not have an accurate date of first diagnosis, incidence rate ratios 
could not be calculated for the hospital discharge data.  Instead we used logistic 
regression to calculate odds ratios for the presence of specific hospital discharges, 
unadjusted and adjusted for potential confounding by women’s year of birth, smoking 
status and social class at time of first pregnancy.  
 
Results:  
We identified from the AMND 46929 women with year of birth before 1968 who were 
resident in Aberdeen City and District at the time of their first pregnancy leading to 
delivery. Women with twins or other multiple pregnancies were excluded. Of these, 
174 women with chronic hypertension were excluded from the analysis. After 
excluding duplicate cases (n=128), 74.8% of the women were linked to one or more 
of SMR01, SMR06 and GRO-S. One woman with death registered prior to delivery 
was excluded from the analysis as an incorrect match. After the various exclusions, 
there were 23,937 normotensive women, 8,891 women who had gestational 
hypertension and 2,026 women who had had pre-eclampsia or eclampsia in their first 
pregnancy; all of whom were linked to at least one register. Follow up started from the 
year of delivery recorded in the AMND. Follow up for death was 1,200,910 woman 
years and that for cancer registration was 1,109,329 woman years. 
Table 1 presents the baseline characteristics of the women in the exposed and 
unexposed groups at the time of their first pregnancy. Compared to women who were 
normotensive in their first pregnancy, women with gestational hypertension or 
preeclampsia/eclampsia were more likely to have a body mass index (BMI) over 30 
kg/m2, but were less likely to be smokers. There were no statistically significant 
differences between the three groups in terms of mean age at first delivery, social 
class and marital status. 
Table 2 shows the number and proportion of deaths occurring in the three groups. 
The mean (standard deviation) age of death in the normotensive, gestational 
hypertension and preeclampsia groups was 64.3 (11.7), 63.9 (12.6) and 64.0 (12.4) 
years respectively. The death rates per 10,000 woman-years of follow-up were 40.2, 
37.6 and 38.8, respectively. Compared to women who were normotensive in their first 
pregnancy, women with gestational hypertension had lower rates of death from any 
cancer, breast and respiratory system cancer, although the IRRs did not remain 
statistically significant after adjusting for smoking, social class and year of birth. 
Women with gestational hypertension also had a higher risk of death from 
cerebrovascular disease {adjusted incident rate ratio (adj. IRR) 1.28, 95% confidence 
interval (CI) 1.03, 1.59}, ischaemic heart disease (adj. IRR 1.35, 95% CI 1.15, 1.59), 
and all circulatory diseases (adj. IRR 1.25, 95% CI 1.11, 1.41); and a lower risk of 
death from non-cancerous respiratory disease (adj. IRR 0.76, 95% CI 0.60, 0.97).  
Compared to normotensive women, women with pre-eclampsia/eclampsia had a 
higher mortality rate from ischaemic heart disease (adj. IRR 1.38, 95% CI 1.03, 1.84) 
and all circulatory diseases (adj. IRR 1.30, 95% CI 1.06, 1.60). None of the incident 
rate ratios for the other mortality outcomes were statistically significant. 
Table 3 presents the chances of having at least one hospital episode due to selected 
conditions in the three groups of women. This table shows the counts of women in 
each group with at least one admission of the specific type as defined by the 
discharge diagnosis.  A woman with at least one admission for hypertension and at 
least one admission for cerebrovascular disease would be counted in both of the 
appropriate discharge diagnosis rows, as well as once in the all circulatory row. 
Compared with normotensive women, those with gestational hypertension were more 
likely to be hospitalised because of any circulatory disease (adjusted odds ratio (adj. 
OR) 1.22, 95% CI 1.15, 1.29), hypertension (adj. OR 1.68, 95% CI 1.55, 1.82), and 
ischaemic heart disease (adj. OR 1.22, 95% CI 1.11, 1.34). The adjusted odds ratios 
of hospital discharge from any circulatory disease (adj. OR 1.20, 95% CI 1.08, 1.33) 
and hypertension (adj. OR 1.79, 95% CI 1.55, 2.05) were significantly higher in 
women with pre-eclampsia/eclampsia, when compared to normotensive women. 
The mean (standard deviation) age at first cancer registration in the normotensive, 
gestational hypertension and preeclampsia groups were 52.4 (14.9), 51.8 (14.5) and 
51.6 (15.0) years respectively. The rates of cancer registration per 10,000 woman-
years of follow-up were 58.5, 52.1 and 48.9, respectively.  Women with gestational 
hypertension had a lower rate of any cancer registration compared to normotensive 
women (adj. IRR 0.91, 95% CI 0.85, 0.96); as did women with pre-
eclampsia/exclampsia (adj. IRR 0.86, 95% CI 0.77, 0.97; Table 4). In addition, 
women with gestational hypertension had a lower rate of cancer of the respiratory 
system (adj. IRR 0.79, 95% CI 0.63, 0.99) and other cancers not specified (which 
included carcinoma-in-situ of the uterine cervix - adj. IRR 0.88, 95% CI 0.81, 0.95). 
When key analyses were repeated excluding women with unknown smoking status, 
the risk estimates were broadly similar in size and direction (tables available on 
request). 
 
 
Discussion: 
We found that women with gestational hypertension or preeclampsia/eclampsia in 
their first pregnancy were more likely to be discharged from hospital with, and have 
higher death rates from, ischaemic heart disease and all circulatory disease 
(including ischaemic heart disease and cerebrovascular disease) than normotensive 
women. Women with hypertensive disorders of pregnancy were also more likely to 
have at least one hospital discharge, but not mortality, from hypertensive disorders 
later in life. There was an overall reduced risk of cancer registration in women with 
gestational hypertension or preeclampsia/eclampsia in their first pregnancy and a 
non-significant lower risk of cancer mortality. We did not find an association between 
hypertensive diseases of pregnancy and all cause mortality. 
The association between preeclampsia/eclampsia and the future cardiovascular 
health of women is now well established. In the first of the two meta-analyses, 
Bellamy et al 6 found that the pooled relative risk of ischaemic heart disease in 
women with a history of preeclampsia was 2.16 (95%CI 1.86, 2.52), hypertension in 
later life was 3.70 (95% CI 2.70, 5.05) and fatal and non-fatal stroke was 1.81 (95% 
CI 1.45, 2.27). McDonald et al 7 found a similar doubling of risk of overall 
cardiovascular disease in women with a history of preeclampsia. Our study supports 
most of the increased cardiovascular risks with preeclampsia/eclampsia found in the 
other studies, although we did not find a statistically significant relationship with fatal 
or non-fatal cerebrovascular events. We also found an increased risk in subsequent 
cardiovascular disease in women with gestational hypertension. In the original 
ASCHW study 3, we observed an increase in risk of hypertension and stroke in later 
life but not admission to hospital, or death, from ischaemic heart disease. Lykke et 
al15 reported a more than a five-fold increase in the risk of subsequent hypertension 
after gestational hypertension. 
Several studies have analysed the risk of all cause mortality and mortality from 
cardiovascular disease in women with hypertensive disorders of pregnancy and 
reported conflicting results. Jonsdottir et al 8 found a dose dependent increase in risk 
of death in women with gestational hypertension, preeclampsia and eclampsia 
compared to women who were normotensive in pregnancy. Almost half of the excess 
risk was attributable to cardiovascular mortality. Using population based Scottish 
data; Smith et al2 reported the additive effects of preeclampsia, preterm delivery and 
delivery of small for date babies on hospital admissions and mortality from ischaemic 
heart disease. More recently, Iversen and Hannaford 10 found a significantly higher 
risk of all cause mortality and mortality from vascular conditions in women with 
toxaemia of pregnancy – the old nomenclature used to describe hypertensive 
disorders of pregnancy. We found a significantly higher risk of cardiovascular 
mortality in women with preeclampsia and gestational hypertension but no difference 
in all cause mortality. It is possible that the excess risk of cardiovascular mortality in 
these women may have been offset by the slight reduction in risk of cancer mortality 
and death from non-cancerous respiratory diseases. 
The relationship between preeclampsia or gestational hypertension and the risk of 
subsequent cancer has received less attention than for cardiovascular outcomes, and 
the literature is less consistent. Similar to our findings, others have also failed to find 
a significant relationship between preeclampsia and future risk of maternal death from 
cancer9,20. A cohort study of women living in Utah, USA found that preeclampsia was 
associated with a statistically significant reduced risk of any cancer later in life 
(hazard ratio: 0.92, 95% CI 0.85 to 0.99) 11.  Conversely, an Israeli cohort study found 
an overall increased risk of cancer incidence following preeclampsia  12 19, mainly due 
to an increased risk of cancers of the breast and ovary 12. While some studies report 
a reducedrisk 11, 16 of breast cancer others have found no such association 9, 17-20. In 
their meta-analysis, Bellamy et al 6 did not find any association between preeclampsia 
and the risk of cancer, overall or for specific sites.  
We report the findings from a large historical cohort  study of women’s health 
following pregnancy and delivery. Following on from our original work3, this new 
analysis benefited from a tenfold increase in the size of the cohort and an increase of 
at least 10 years’ follow up. A study on such a large scale was made feasible by the 
record linkage of routinely collected data, rather than a de novo study. The 
contemporaneous recording of data in both the AMND and the SMR databases 
reduces the potential for recall bias. Both databases are subject to quality control 
measures, enabling us to be confident in both the exposure and outcome variables. 
Apart from our previous report from the original ASCHW cohort, 3 which was based 
on smaller numbers, this is, to our knowledge, the only other primary study to take 
such a comprehensive approach. 
The study, however, has limitations which are partly due to the nature of the record 
linkage process. Only 74% of the cohort identified from the AMND was matched with 
the SMR databases. The remainder may have left Scotland or remained alive with no 
health events requiring a hospital admission or cancer registration. We cannot rule 
out selection bias resulting from this. However, the women whose AMND records 
could not be matched with the SMR database were evenly distributed across the 
three groups of women being compared, suggesting minimal bias (tables available on 
request). Moreover, the probability matching technique used for linkage of records is 
subject to at least 3% error in either direction.  We were only able to adjust for the 
potential confounding factors of year of birth, social class and smoking.  In addition, 
smoking data were missing for a number of women.  Our findings, therefore, may be 
influenced by residual confounding especially by BMI. Lastly, we were only able to 
assess outcomes that warranted hospital admissions, thereby missing asymptomatic 
cases, and cases managed exclusively in the community. This is likely to have 
greatest impact on outcomes like chronic hypertension, where most cases are 
managed in the community. 
Despite these limitations, our results suggest an increased risk of fatal and non-fatal 
cardiovascular disease among women who have had a hypertensive problem in 
pregnancy. The mechanisms by which such effects occur remain elusive. 
Controversy remains about whether the effects occur because pregnancy unmasks a 
predisposition to vascular disease (i.e. pregnancy is a risk marker of vascular 
disease) and/or whether hypertensive disorders in pregnancy cause permanent 
damage to the vascular system (i.e. they are risk factors for cardiovascular 
disease)21.  
In addition to wanting to know the cause underlying the association between 
hypertensive disorders in pregnancy and cardiovascular risk, clinicians and their 
patients are likely to want to know when the risk first appears, and what can be done 
about it. More work is needed to identify the timing of risk increase. Until this is 
identified, women with a history of hypertensive problems in pregnancy should be 
informed that they have an increased risk of cardiovascular disease later in life and 
that they should follow current advice for good cardiovascular health (i.e. do not 
smoke, drink in moderation, avoid being overweight, be active and eat a healthy diet). 
Although some authorities recommend that all women who have had a hypertensive 
disorder in pregnancy should have their blood pressure measured22,  other guidelines 
suggest that, in the absence of indicators of high cardiovascular risk (e.g. a previous 
cardiovascular event, history of diabetes or familial hypercholesterolaemia), all adults 
aged 40 and older should have their cardiovascular risk assessed every five years23. 
As a minimum, women with a history of a hypertensive problem in pregnancy should 
be strongly encouraged to take part in such screening.   
 
Conclusions: 
Our results indicate that women with a history of gestational hypertension or 
preeclampsia/eclampsia have an increased risk of hospital discharge for, and 
mortality from, all circulatory disease, as well as some specific cardiovascular events; 
and a reduced risk of being registered as having had cancer later in life. No 
relationship was apparent between pregnancy induced hypertension and all cause 
mortality. 
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 Table 1.  Baseline characteristics of study cohort at antenatal booking unless stated 
otherwise 
 
 Normotensive  
 
Gestational 
hypertension  
 
Preeclampsia/ 
eclampsia  
 
p-value 
Total  23,937 (68.4%) 8,891 (25.4%) 2,026 (5.8%)  
Mean (SD) age at 1st 
delivery (years) 
 
24.25 (4.94) 24.34 (4.84) 24.57 (5.10) 0.13 
No(%) BMI categories* 
(kg/m2) 
<20 
20 – 24.99 
25 – 29.99 
30 – 34.99 
>35 
Missing 
 
 
 
1,356 (5.7%) 
6,944 (29.0%) 
2,114 (8.8%) 
308 (1.3%) 
79 (0.3%) 
13,136 (54.9%) 
 
 
330 (3.7%) 
2,424 (27.3%) 
1,259 (14.2%) 
292 (3.3%) 
101 (1.1%) 
4,485 (50.4%) 
 
 
67 (3.3%) 
536 (26.5%) 
277 (13.7%) 
73 (3.6%) 
31 (1.5%) 
1,042 (51.4%) 
0.01 
No  (%) in social class 
non-manual 
No (%) in social class 
manual 
Missing social class 
 
6,512 (27.2%) 
 
12,744 (53.2%) 
 
4,681 (19.6%) 
2,451 (27.6%) 
 
4,507 (50.7%) 
 
1,933 (21.7%) 
534 (26.4%) 
 
1,033 (51.0%) 
 
459 (22.7%) 
0.49 
No (%) who had ever 
smoked* 
No (%) never smoked 
Missing smoking 
 
6,036 (25.2%) 
 
9,115 (38.1%) 
8,786 (36.7%) 
2,048 (23.0%) 
 
4,135 (46.5%) 
2,708 (30.5%) 
385 (19.0%) 
 
1,032 (50.9%) 
609 (30.1%) 
<0.01 
No (%) single 2,605 (10.9%) 914 (10.3%) 212 (10.5%) 0.43 
No (%) married/living 
as married 
21,322 (89.1%) 7,974 (89.7%) 1,812 (89.4%)  
Missing marital status 10 (0%) 3 (0%) 2 (0.2%)  
*p<0.05 compared with normotensive group. SD= Standard Deviation, BMI= Body Mass Index 
 Table 2.  Unadjusted and adjusted incident rate ratios for all- and cause-specific mortality in all traced women; 
normotensive women as reference group  
 
Cause  
 
 Normotensive 
(n=23,937) 
Deaths 
 
Gestational hypertension  (n=8,891) 
  
Pre-eclampsia/eclampsia  (n=2,026) 
 
Deaths  
 
Unadjusted 
incident rate 
ratio (95% CI)  
 
Adjusted* incident 
rate ratio (95% CI)  
  
Deaths  
 
Unadjusted 
incident rate 
ratio  (95% CI)  
 
Adjusted* incident rate 
ratio (95% CI)  
 
All causes 3344 (14.0%) 1134 (12.8%) 0.94 (0.88,1.00) 1.00 (0.94,1.07)  266 (13.1%) 0.96 (0.85,1.09) 1.00 (0.88,1.13) 
Any Cancer 
Specific site: 
1502 (6.3%) 465 (5.2%) 0.85 (0.77,0.95) 0.91 (0.82,1.01)  102 (5.0%) 0.82 (0.67,1.01) 0.86 (0.70,1.05) 
- Breast 
- Uterus 
- Ovary 
- Skin 
- Respiratory 
- GIT 
- Others 
307 (1.3%) 
52 (0.2%) 
96 (0.4%) 
19 (0.1%) 
361 (1.5%) 
344 (1.4%) 
323 (1.3%) 
86 (1.0%) 
19 (0.2%) 
31 (0.3%) 
5 (0.1%) 
96 (1.1%) 
121 (1.4%) 
107 (1.2%) 
0.77 (0.61,0.98) 
1.01 (0.60,1.70) 
0.89 (0.59,1.34) 
0.73 (0.27,1.94) 
0.73 (0.59,0.92) 
0.97 (0.79,1.19) 
0.91 (0.73,1.14) 
0.80 (0.63,1.01) 
1.05 (0.62,1.78) 
0.93 (0.62,1.39) 
0.75 (0.28,2.01) 
0.81 (0.65,1.01) 
1.02 (0.83,1.26) 
0.97 (0.78,1.21) 
 27 (1.3%) 
3 (0.1%) 
4 (0.2%) 
4 (0.2%) 
24 (1.2%) 
20 (1.0%) 
20 (1.0%) 
1.07 (0.72,1.58) 
0.70 (0.22,2.24) 
0.51 (0.19,1.37) 
2.55 (0.87,7.50) 
0.81 (0.53,1.22) 
0.71 (0.45,1.11) 
0.75 (0.48,1.18) 
1.08 (0.73,1.60) 
0.74 (0.23,2.38) 
0.52 (0.19,1.41) 
2.59 (0.88,7.63) 
0.87 (0.57,1.31) 
0.71 (0.45,1.12) 
0.78 (0.50,1.22) 
Cerebrovascular 
disease 
266 (1.1%) 117 (1.3%) 1.21 (0.98,1.51) 1.28 (1.03,1.59)  29 (1.4%) 1.32 (0.90,1.94) 1.27 (0.87,1.87) 
Ischaemic heart 
disease 
467 (2.0%) 214 (2.4%) 1.28 (1.08,1.50) 1.35 (1.15,1.59)  52 (2.6%) 1.38 (1.04,1.84) 1.38 (1.03,1.84) 
Hypertensive 
disease 
13 (0.1%) 8 (0.1%) 1.70 (0.70,4.10) 1.74 (0.72,4.20)  2 (0.1%) 1.87 (0.42,8.27) 1.83 (0.41,8.14) 
Other circulatory 
disease 
176 (0.7%) 58 (0.7%) 0.99 (0.66,1.17) 1.00 (0.69,1.24)  18 (0.9%) 1.14 (0.70,1.85) 1.12 (0.68,1.83) 
All circulatory 
disease 
922 (3.9%) 397 (4.5%) 1.19 (1.06,1.34) 1.25 (1.11,1.41)  101 (5.0%) 1.33 (1.08,1.63) 1.30 (1.06,1.60) 
Respiratory** 335 (1.4%) 85 (1.0%) 0.70 (0.55,0.89) 0.76 (0.60,0.97)  17 (0.8%) 0.62 (0.38,1.00) 0.63 (0.39,1.03) 
Digestive** 152 (0.6%) 48 (0.5%) 0.87 (0.63,1.21) 0.92 (0.67,1.28)  13 (0.6%) 1.04 (0.59,1.83) 1.11 (0.63,1.95) 
Kidney disease 21 (0.1%) 13 (0.1%) 1.71 (0.86,3.41) 1.81 (0.90,3.62)  3 (0.1%) 1.73 (0.52,5.81) 1.72 (0.51,5.79) 
Other causes 412 (1.7%) 126 (1.4%) 0.84 (0.69,1.03) 0.91 (0.74,1.11)  30 (1.5%) 0.88 (0.61,1.28) 0.94 (0.65,1.36) 
 
*Adjusted for year of birth, social class and smoking. ** Excluding cancer 
Statistically significant incident rate ratios are shown in bold 
Table 3.  Unadjusted and adjusted odds ratios (95% CI) of at least one hospital discharge for selected causes; normotensive women as 
reference group. 
Discharge diagnosis  
 
Normotensive 
(n=23,937) 
Hospital 
discharges  
 
Gestational Hypertension  (n=8,891) Pre-eclampsia/eclampsia  (n=2,026) 
No of discharges  
 
Unadjusted odds 
ratio (95% CI)  
 
Adjusted* odds 
ratio  (95% CI)  
  
No of discharges  
 
Unadjusted odds 
ratio (95% CI)  
 
Adjusted* odds ratio  (95% 
CI)  
 
All circulatory 7273 (30.4%) 2926 (32.9%) 1.12 (1.07,1.18) 1.22 (1.15,1.29)  662 (32.7%) 1.11 (1.01,1.23) 1.20 (1.08,1.33) 
Hypertension 2260 (9.4%) 1201 (13.5%) 1.50 (1.39,1.61) 1.68 (1.55,1.82)  290 (14.3%) 1.60 (1.41,1.83) 1.79 (1.55,2.05) 
Cerebrovascular 
disease 
1004 (4.2%) 361 (4.1%) 0.97 (0.86,1.09) 1.04 (0.91,1.18)  94 (4.6%) 1.11 (0.90,1.38) 1.16 (0.93,1.45) 
Ischaemic heart disease 1882 (7.9%) 756 (8.5%) 1.09 (1.00,1.19) 1.22 (1.11,1.34)  172 (8.5%) 1.09 (0.92,1.28) 1.18 (0.99,1.41) 
Arterial diseases 550 (2.3%) 218 (2.5%) 1.07 (0.91,1.25) 1.16 (0.99,1.36)  56 (2.8%) 1.21 (0.92,1.60) 1.28 (0.96,1.70) 
Pulmonary embolism 294 (1.2%) 90 (1.0%) 0.82 (0.65,1.04) 0.86 (0.67,1.09)  23 (1.1%) 0.92 (0.60,1.42) 0.95 (0.62,1.45) 
Kidney disease 741 (3.1%) 283 (3.2%) 1.03 (0.90,1.18) 1.09 (0.95,1.25)  71 (3.5%) 1.14 (0.89,1.46) 1.20 (0.93,1.54) 
 
* Adjusted for year of birth, social class and smoking 
 
Statistically significant odds ratios are shown in bold 
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Table 4.  Unadjusted and adjusted incident rate ratios for first cancer registration in 1 
all traced women; normotensive women as reference group  2 
Cancer  
 
Normotensive 
(n+=23772) 
Gestational Hypertension  
(n+=8852) 
Pre-eclampsia/eclampsia  
(n+=2019) 
 
Number of 
cancer 
registrations 
 
Number of 
cancer 
registrations 
 
Unadjusted 
incident 
rate ratio 
(95% CI)  
 
Adjusted* 
incident 
rate ratio 
(95% CI)  
 
Number of 
cancer 
registrations  
 
Unadjusted 
incident 
rate ratio 
(95% CI)  
 
Adjusted* 
incident 
rate ratio 
(95% CI)  
 
All cancers 
Specific 
site: 
4482 (18.9%) 1455 (16.4%) 0.89 
(0.84,0.95) 
0.91 
(0.85,0.96) 
312 (15.5%) 0.84 
(0.75,0.94) 
0.86 
(0.77,0.97) 
Breast 862 (3.6%) 292 (3.3%) 0.93 
(0.81,1.06) 
0.93 
(0.81,1.06) 
58 (2.9%) 0.81 
(0.62,1.05) 
0.80 
(0.62,1.05) 
Uterus 183 (0.8%) 75 (0.8%) 1.13 
(0.86,1.47) 
1.14 
(0.87,1.49) 
11 (0.5%) 0.72 
(0.39,1.33) 
0.74 
(0.40,1.35) 
Ovary 74 (0.3%) 23 (0.3%) 0.85 
(0.53,1.36) 
0.88 
(0.55,1.41) 
7 (0.3%) 1.14 
(0.52,2.47) 
1.20 
(0.55,2.62) 
Skin 247 (1.0%) 82 (0.9%) 0.91 
(0.71,1.17) 
0.91 
(0.71,1.17) 
17 (0.8%) 0.83 
(0.51,1.35) 
0.82 
(0.50,1.35) 
Respiratory 363 (1.5%) 94 (1.1%) 0.71 
(0.57,0.89) 
0.79 
(0.63,0.99) 
22 (1.1%) 0.73 
(0.47,1.12) 
0.80 
(0.52,1.23) 
GI tract 477 (2.0%) 156 (1.8%) 0.90 
(0.75,1.08) 
0.94 
(0.79,1.13) 
32 (1.6%) 0.81 
(0.56,1.15) 
0.82 
(0.57,1.17) 
Other 
cancers 
2276 (9.6%) 733 (8.3%) 0.88 
(0.81,0.96)  
0.88 
(0.81,0.95) 
165 (8.2%) 0.87 
(0.74,1.02) 
0.89 
(0.76,1.05) 
*Adjusted for year of birth, social class and smoking 3 
 4 
Statistically significant incident rate ratios are shown in bold 5 
 6 
+ n reduced due to exclusion from this analysis of 211 women who had cancer prior to 7 
delivery or had a date of delivery after the final date of follow-up from the cancer registry. 8 
 9 
